

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**Appl. Serial No.:** 10/623,189

**Patent No.:** 7,183,254 B2

**Inventors:** Alexander De Paoli, et al.

**Filed:** July 18, 2003

**Title:** USE OF LEPTIN FOR TREATING HUMAN  
LIPOATROPHY AND METHOD OF DETERMINING  
PREDISPOSITION TO SAID TREATMENT

**Confirmation No.:** 3581

**TC/A.U.:** 1646

**Examiner:** O'Hara, Eileen B.

### Request for Certificate of Correction Under 37 C.F.R. § 1.323

#### Attention: Certificate of Correction Branch

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. § 1.323, Patentee hereby requests that a Certificate of Correction be issued to correct errors in the claims for the above-identified patent. Patentee notes that the correction requested herein is necessitated as a result of Applicant error. Specifically, two co-assignees or record were inadvertently, and without deceptive intent, omitted from the issue fee transmittal form that was completed and filed in order to effect payment of the issue and issuance of the above identified case.

In support of this Request for Certificate of Correction Under 37 C.F.R. § 1.323, Applicant submits copies of the following Documents as evidence:

1. Patent Assignment Abstract of Title printed from USPTO website March 12, 2008, indicating that the following entities have been recorded co-assignees of the above-identified issued US Patent, and that each executed assignment has been

---

CERTIFICATE OF EXPRESS MAILING UNDER 37 C.F.R. 1.10 OR  
TRANSMISSION UNDER 37 C.F.R. 1.8

I hereby certify that this paper (along with anything referred to as being attached or enclosed) is being electronically filed with the USPTO via the USPTO EFS-Web electronic filing system on the date shown below.

March 12, 2008  
Date of Deposit

/Michael D. Ruse, Jr.  
Signature of Person Mailing Paper

Michael D. Ruse, Jr.  
Name of Person Mailing Paper

accorded a valid reel and frame number: The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services, reel and frame number 017036/0674; Board of Regents, The University of Texas System, reel and frame number 017036/0693; and Amgen Inc., reel and frame number 017036/00640;

2. Copy of Issue Fee Transmittal (PTOL-85) mailed November 29, 2006, indicating only Amgen Inc. as assignee; and
3. Copy of cover page of U.S. Patent No. 7,208,577, indicating only Amgen, Inc. as assignee in Item (73).

Therefore, because, ownership of the above-identified issued US Patent has been properly recorded by the United States Patent and Trademark Office as evidenced by the valid reel and frame numbers which correspond to fully executed assignments to each respective assignee, the omission of The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services, and the Board of Regents, The University of Texas System from item (73) on the cover page of the subject Patent is in error and should be corrected. Therefore, Applicant respectfully requests the issuance of the Certificate of Correction as submitted herewith. Because the omission of The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services, and the Board of Regents, The University of Texas System from item (73) resulted from Applicant's inadvertent failure to indicate these entities as co-assignees on the Issue Fee Transmittal form that was filed in the above-identified case, the error constitutes an error on the part of Applicant. Accordingly, Applicant herewith provides the associated fee as required under 37 C.F.R. § 1.20(a).

Additionally, if any other fees should become due in connection with this submission the commissioner is hereby authorized to charge any fee deficiency, and/or credit any overpayment, to Deposit Account No. 010535, referencing docket number 1311US-CON.

Respectfully submitted,  
AMYLIN PHARMACEUTICALS, INC.

Date: March 12, 2008

/Michael D. Ruse, Jr./  
Michael D. Ruse, Jr.  
Registration No. 55,900

**AMYLIN PHARMACEUTICALS, INC.**  
9360 Towne Centre Drive  
San Diego, CA 92121  
Telephone: (858) 552-2200  
Facsimile: (858) 552-1936